Soluble urokinase plasminogen activator receptor (suPAR) is a potential biomarker of stage III-IV, grade C periodontitis through the impact of post-radiotherapy on head and neck cancer patients

Key Points

Key points are not available for this paper at this time.

Abstract

The study was registered retrospectively; clinicaltrials.gov identifier: NCT06529588. Date of registration: July 31, 2024 https://clinicaltrials.gov/study/NCT06529588 .

Bookmark

View Full Paper

Cite This Study

Al-Kubaisi et al. (Fri,) studied this question.

synapsesocial.com/papers/69da7e1b84371aa676a3d382 https://doi.org/https://doi.org/10.1186/s12903-024-04801-w

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Elevated soluble urokinase receptor values in CSF, age and bacterial meningitis infection are independent and additive risk factors of fatal outcome2011 · 32 citations
2Oncoproteomic and gene expression analyses identify prognostic biomarkers for second primary malignancy in patients with head and neck squamous cell carcinoma2019 · 37 citations
3Radioimmunotherapy for the treatment of head and neck cancer2019 · 104 citations
4Soluble urokinase receptor levels correlate with number of circulating tumor cells in acute myeloid leukemia and decrease rapidly during chemotherapy.2000 · 103 citations
5Regulation of cell signalling by uPAR2009 · 967 citations

Bookmark

View Full Paper